Structured evidence table for Citrus Bioflavonoid Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Citrus Bioflavonoid Blood Pressure Randomized Trial | Results At the end of the intervention, the nutraceutical group demonstrated improved postprandial glucose metabolism, including a 5% reduction in 2-h OGTT glucose and preservation of active GLP-1 levels. | 2 | Cesar T (2025) | Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial. |
| Citrus Bioflavonoid Blood Pressure Randomized Trial | In contrast, the placebo group exhibited a decline in GLP-1 and increased insulin resistance. | 2 | Cesar T (2025) | Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial. |
| Citrus Bioflavonoid Blood Pressure Randomized Trial | Additionally, systolic blood pressure was reduced by 4%, potentially associated with improved antioxidant status and higher dietary potassium intake. | 2 | Cesar T (2025) | Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial. |
| Citrus Bioflavonoid Blood Pressure Randomized Trial | Background and objective Combining natural compounds with conventional drugs is an emerging strategy to improve the management of type 2 diabetes and its precursor, prediabetes. | 2 | Cesar T (2025) | Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial. |
| Citrus Bioflavonoid Blood Pressure Randomized Trial | The downstream result is twofold: in skeletal muscle, glucose uptake is impaired; in the liver, glucose production remains inappropriately elevated [,,,]. | 3 | Shimu Shakila Jahan (2025) | Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance |
| Citrus Bioflavonoid Blood Pressure Randomized Trial | Although these conditions often coexist, emerging evidence suggests that hepatic inflammation and lipotoxicity, not simple steatosis, are the more potent drivers of metabolic impairment [,,]. | 3 | Shimu Shakila Jahan (2025) | Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance |
| Citrus Bioflavonoid Blood Pressure Randomized Trial | The result is an overproduction of reactive oxygen species (ROS), driven not only by mitochondrial electron transport chain leakage but also by upregulated NADPH oxidase (NOX) activity [,,] []. | 3 | Shimu Shakila Jahan (2025) | Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance |
| Citrus Bioflavonoid Blood Pressure Randomized Trial | 1 2 3 4 5 6 It begins quietly, an expanding waistline, a subtle shift in blood sugar levels, a creeping fatigue. | 3 | Shimu Shakila Jahan (2025) | Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance |
Source documents